Vimarsana
Biggest News Aggregation in the World

Page 39 - Cautionary Note News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cautionary Note. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cautionary Note Today - Breaking & Trending Today

Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia - Vimarsana News

Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an...

Oncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022 - Vimarsana News

Oncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Oncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022 - Vimarsana News

Oncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022

AGOURA HILLS, CA, Dec. 14, 2021 -- Oncotelic Therapeutics, Inc. , a leading developer of TGF-β therapeutics for oncology and virology, today announced that the Company’s Chief Clinical... | December 14, 2021

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease - Vimarsana News

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an...

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease - Vimarsana News

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an...